Oxymetazoline - Allergan

Drug Profile

Oxymetazoline - Allergan

Alternative Names: AGN-199201; V-101

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Vicept Therapeutics
  • Developer Allergan
  • Class Decongestants; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Erythema
  • Phase II Presbyopia

Most Recent Events

  • 24 May 2016 Allergan expects the PDUFA action date to be in the first half of 2017 for Oxymetazoline for Erythema (Topical, Cream)
  • 01 May 2016 Allergan initiates a phase II trial for Presbyopia (Combination therapy) in USA (NCT02780115)
  • 01 Apr 2016 Phase-II clinical trials in Presbyopia (Combination therapy) in USA (Ophthalmic) (NCT02595528)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top